Loading patent…
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsLoic Pierre Deleyrolle, Elias Sayour
Estimating the term…
The present disclosure provides compositions comprising a liposome comprising a cationic lipid and nucleic acid molecules comprising a sequence of a nucleic acid molecule expressed by slow-cycling cells (SCCs). The present disclosure also provides methods of preparing an anti-tumor liposome composition. In exemplary embodiments, the method comprises (a) isolating SCCs from a mixed tumor cell population in accordance with any one of the presently disclosed in vitro method of isolating SCCs from a mixed tumor cell population, (b) extracting nucleic acid molecules from the isolated SCCs, and (c) mixing the nucleic acid molecules with a cationic lipid to make an anti-tumor liposome composition. The method of preparing an anti-tumor liposome composition in alternative embodiments comprises mixing at least one SCC transcriptome nucleic acid molecule as described herein with a cationic lipid to make an anti-tumor liposome composition. Tumor treatment methods are furthermore provided by the present disclosure.
A composition comprising a liposome comprising a cationic lipid and nucleic acid molecules comprising a sequence of a nucleic acid molecule expressed by slow cycling cells (SCCs).
The composition of any one of the preceding claims, comprising nucleic acid molecules encoded by at least one gene listed in Supplemental Table 1.
A method of preparing an anti-tumor liposome composition comprising,
A method of preparing an anti-tumor liposome composition comprising mixing a nucleic acid molecule encoded by at least one gene listed in Supplemental Table 1 with a cationic lipid to make an anti-tumor liposome composition.
Use of the composition of any one of the preceding claims for treatment of a subject with a tumor or cancer.
Use of the composition of any one of the preceding claims for immunizing a subject against tumorigenesis.
A method of isolating slow cycling cells (SCCs) from a mixed tumor population, comprising separating cells of the mixed tumor population using a flow cytometer based on proliferation rate, mitochondrial content, lipid content or a combination thereof.
Dependencies are inferred from the claim text.